Carnegie Lake Advisors LLC Sells 5,079 Shares of Johnson & Johnson $JNJ

Carnegie Lake Advisors LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 36.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,010 shares of the company’s stock after selling 5,079 shares during the quarter. Johnson & Johnson comprises 2.1% of Carnegie Lake Advisors LLC’s portfolio, making the stock its 14th largest position. Carnegie Lake Advisors LLC’s holdings in Johnson & Johnson were worth $2,385,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Elite Wealth Management Inc. bought a new position in Johnson & Johnson during the 3rd quarter valued at approximately $6,117,000. M Holdings Securities Inc. bought a new position in shares of Johnson & Johnson during the third quarter valued at $8,091,000. Avantax Planning Partners Inc. raised its position in shares of Johnson & Johnson by 1.0% in the 3rd quarter. Avantax Planning Partners Inc. now owns 45,842 shares of the company’s stock worth $12,136,000 after purchasing an additional 449 shares during the last quarter. Brighton Jones LLC boosted its stake in Johnson & Johnson by 5.4% in the 3rd quarter. Brighton Jones LLC now owns 60,818 shares of the company’s stock worth $16,101,000 after purchasing an additional 3,093 shares in the last quarter. Finally, Candriam S.C.A. grew its position in Johnson & Johnson by 1.3% during the 3rd quarter. Candriam S.C.A. now owns 516,642 shares of the company’s stock valued at $137,276,000 after purchasing an additional 6,468 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Johnson & Johnson Trading Down 0.0%

Johnson & Johnson stock opened at $276.14 on Monday. Johnson & Johnson has a 52-week low of $185.12 and a 52-week high of $282.02. The company has a market cap of $664.76 billion, a P/E ratio of 41.84, a P/E/G ratio of 2.73 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The business has a 50-day simple moving average of $265.91 and a two-hundred day simple moving average of $248.30.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on JNJ shares. The Goldman Sachs Group reiterated a “buy” rating and issued a $282.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Citigroup increased their target price on Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Argus set a $300.00 target price on Johnson & Johnson in a report on Wednesday, July 29th. HSBC boosted their price target on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Finally, Erste Group Bank downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $275.92.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.